COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS
The present invention relates to novel perfluorinated precursors for the production of F-18 labeled radiotracers for Positron Emission Tomography (PET) and processes for radiolabeling and purification using these precursors. The invention also comprises radiopharmaceutical kits using these precursors and processes.
1 . A compound of Formula I:
R-L-M( x ) (I)
wherein
R is a targeting substrate.
L is a leaving group suitable for a substitution with [F-18]fluoride,
M is a perfluorinated substituent, bearing 6-30 fluorine atoms,
X has the value of at least 1,
and wherein R-L-M is not
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Heptadecafluoro-octane-1-sulfonic acid 2-(2-sulfamoyl-benzothiazol-6-yloxy)-ethyl ester, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Heptadecafluoro-octane-1-sulfonic acid 2-(4-sulfamoyl-phenyl)-ethyl ester, 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Heptadecafluoro-octane-1-sulfonic acid 4-sulfamoyl-benzyl ester, Perfluoro-alkyl-1-sulfonic acid 1,2-bis-(aryl)-2-(perfluoroalkyl-1-sulfonyloxy)-vinyl ester, hexahydro-2,6-bis(perfluoroalkylsulfonyloxy)-cyclopenta[1,2-c:4,5-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone, 3a,4,4a,7,8,8a-hexahydro-2,6-bis(perfluoroalkylsulfonyloxy)-4,8-ethenobenzol[1,2-c:4,5-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone.
2 . A compound according to claim 1 , wherein R is selected from the group consisting of a synthetic small molecule, a pharmaceutically active compound (drug), a metabolite, a signaling molecule, an hormone, a peptide, a protein, a receptor antagonist, a receptor agonist, a receptor inverse agonist, a vitamin, an essential nutrient, an amino acid, a fatty acid, a lipid, a nucleic acid, a mono-, di-, tri- or polysaccharide, a steroid, hormones, glucose, galactose, fructose, mannitol, sucrose, stachyose, sorbose, and derivatives thereof, glutamine, glutamate, tyrosine, leucine, methionine, tryptophan, acetate, choline, thymidine, folate, methotrexate, Arg-Gly-Asp peptides, chemotactic peptides, alpha melanotropin peptide, somatostatin, bombesin, human pro-insulin connecting peptides and analogues thereof, GPIIb/IIIa-binding compounds, PF4-binding compounds, αvβ3, αvβ6, or α4β1 integrin-binding compounds, somatostatin receptor binding compounds, GLP-1 receptor binding compounds, sigma 2 receptor binding compounds, sigma 1 receptor binding compounds, peripheral benzodiazepine receptor binding compounds, epidermal growth factor receptor binding compounds, PSMA binding compounds, estrogen receptor binding compounds, androgen receptor binding compounds, serotonin transporter binding compounds, neuroepinephrine transporter binding compounds, dopamine transporter binding compounds, LAT1 transporter binding compounds, and any combinations thereof.
3 . A compound according to claims 1 - 2 , wherein R specifically binds to a receptor or enzyme or integrin or is specifically transported by a transporter that is preferentially expressed at a pathologic site within the mammalian body, preferably wherein the receptor or enzyme or integrin or transporter is exclusively expressed at a pathologic site within the mammalian body or wherein R specifically binds to a site of infection, inflammation, cancer, platelet aggregation, angiogenesis, necrosis, ischemia, or tissue hypoxia, angiogenic vessels, Alzheimer's disease plaques, atherosclerotic plaques, pancreatic islet cells, thrombi, serotonin transporters, neuroepinephrin transporters, LAT1 transporters, apoptotic cells, macrophages, neutrophils, EDB fibronectin, receptor tyrosine kinases, or cardiac sympathetic neurons.
4 . A compound according to claims 1 - 3 , wherein L is O—SO 2 and L is attached to an alkylic carbon atom of R.
5 . A compound according to claims 1 - 4 , wherein M is selected from the group comprising:
T
Ar-T
O-T
branched or non-branched (C 1 -C 6 )alkyl-T
branched or non-branched (C 1 -C 6 )alkoxy-T
branched or non-branched (C 1 -C 6 )alkenyl-T
(CF 2 ) p —O-T
(CF 2 ) p —Ar-T
branched or non-branched (C 1 -C 6 )alkyl-Ar-T
wherein:
n is 1-2
T is selected from the group comprising:
branched or non-branched (C 3 -C 10 )perfluoroalkyl
((CF 2 ) t —O) m —(CF 2 ) p —F
t is 1-4
m=3-10
p is 1-2.
6 . A process of preparing a fluorine-18 labeled compound R- 18 F comprising fluorination of compound of formula I according to claims 1 - 5 with a [F-18]fluoride ion source.
7 . A process according to claim 6 wherein the fluoride ion source is selected from the group comprising:
potassium fluoride
caesium fluoride
tetraalkylammonium fluoride.
8 . A process according to claims 6 - 7 wherein the fluorination reaction is carried out in homogeneous solution.
9 . A process according to claims 6 - 8 comprising a purification step.
10 . A process according to claim 9 wherein the purification step is a solid phase extraction.
11 . A process according to claims 9 - 10 wherein the purification step is a solid phase extraction using a perfluorinated stationary phase.
12 . A process according to claim 9 wherein the purification step is a liquid phase extraction.
13 . A process according to claim 11 wherein the purification step is a liquid phase extraction using a perfluorinated solvent.
14 . A process according to claims 6 - 13 wherein the radiolabeled compound R- 18 F is further converted to the final product R′- 18 F after purification of R- 18 F.
15 . The kit for carrying out a process according to any one of claims 6 to 14 comprising a compound of formula I according to claims 1 - 5 .
16 . A process of preparing a fluorine-18 labeled compound Q- 18 F comprising nucleophilic fluorination of compound of formula II Q-L-M, wherein
Q is an organic moiety,
L is a leaving group suitable for a substitution with [F-18]fluoride,
M is a perfluorinated substituent, bearing 6-30 fluorine atoms,
Wherein the process involves a purification step, that makes use of the properties of perfluorinated moiety M.